is associated with urinary manifestations, whereas all other species are associated with hepatointestinal disease.
Certain human genes may modify the susceptibility to infection and subsequent morbidity.
Although efficacy has been demonstrated in studies of adolescent patients with schizophrenia at doses between 1 mg to 6 mg per day, no additional benefit was observed above 3 mg per day, and higher doses were associated with more adverse events.
Doses higher than 6 mg per day have not been studied.
Moreover, given that the lungs have direct contact with the environment through inhalation and receive approximately 50% of the cardiac output with each beat of the heart, they may be adversely affected by hazardous agents from the outside world or other pathologic processes not primarily located in the lungs.
The range of topics discussed herein is limited by design to deaths due to disease and largely foregoes discussion of more forensically relevant issues relating to toxicology or trauma.
In a single study supporting once-daily dosing, the efficacy results were generally stronger for 8 mg than for 4 mg.Schistosomal antigens provoke a triphasic immune response composed of an innate and two overlapping adaptive phases, TH1- then TH2-dominated phase.Morbidity mirrors this immune response, with early allergic reactions, followed by subacute local inflammatory lesions around tissue-deposited ova, and subsequent lifelong chronic fibrotic manifestations.The effective dose range is 1 mg to 6 mg per day, as studied in the short-term, placebo-controlled trials.In these trials, short-term (3 week) anti-manic efficacy was demonstrated in a flexible dosage range of 1 mg to 6 mg per day The initial dose is 0.5 mg once daily, administered as a single-daily dose in the morning or evening.